Serum anti-TOPO48 autoantibody as a biomarker for early diagnosis and prognosis in patients with esophageal squamous cell carcinoma - 01/06/18
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Serum anti-TOPO48 autoantibody levels in ESCC patients were significantly higher than that in healthy controls and patients with esophageal benign tumors. |
• | The percentage of sera with a positive level of anti-TOPO48 autoantibody was significantly higher in early stage ESCC when compared to that in advanced stage of the disease. |
• | Anti-TOPO48 autoantibody alone might be a relative promising cancer-associated autoantibody to aid early detection of ESCC when compared to other autoantibodies in the present cohort study and/or previously published studies. |
• | The sensitivity of cancer detection was obviously increased when combined anti-TOPO48 with SCC-Ag and anti-P53 autoantibody without change specificity. |
• | Anti-TOPO48 autoantibody may be a positive prognostic marker for ESCC patients. |
Summary |
Background and aim |
We previously reported a novel tumor associated antigen (TTA) with molecular weight around 48kDa that is a fragment derived from human DNA-topoiomerase I (TOP1). We termed the novel TAA as TOPO48 and termed autoantibody against the TAA as anti-TOPO48 autoantibody. The aim of this study is to further investigate the clinical applications of the autoantibody in patients with esophageal squamous cell carcinomas (ESCC).
Methods |
Serum levels of the anti-TOPO48 autoantibody in 112 ESCC patients, 112 age- and gender-matched healthy controls and 75 patients with esophageal benign tumors were determined by using a specific anti-TOPO48 autoantibody ELISA. Then, we statistically evaluated its clinical significance.
Results |
We found that serum anti-TOPO48 autoantibody levels in ESCC patients were significantly higher than that in healthy controls and benign tumor patients (P=0.001). The percentage of sera with a positive level of anti-TOPO48 autoantibody in early stages was significantly higher than that in advanced stages of the cancer patients when the maximum level of healthy control sera was taken as a cut-off value (P=0.001). The area under ROC curve was 0.863 (95% CI=0.797–0.928) for healthy controls vs. early stage ESCC. In addition, patients with positive anti-TOPO48 autoantibody had significantly higher survival rate and longer survival time than that with negative anti-TOPO48 autoantibody in cancer patients (P=0.038, 0.025 and 0.047 for all stages, early stage and advanced stage, respectively).
Conclusions |
Our results suggest that anti-TOPO48 autoantibody may be a potentially useful biomarker for early diagnosis and prognosis of ESCC.
Le texte complet de cet article est disponible en PDF.Keywords : ESCC, TOPO48, Anti-TOPO48 autoantibodies, Early diagnosis, Prognosis
Plan
Vol 42 - N° 3
P. 276-284 - juin 2018 Retour au numéro
Article précédent
- Association of NLRP3 single nucleotide polymorphisms with ulcerative colitis: A case-control study
- S. Hanaei, M. Sadr, A. Rezaei, S. Shahkarami, N. Ebrahimi Daryani, A.Z. Bidoki, N. Rezaei
- Histology of the mesorectal lymphatics explains aspects of rectal cancer
- Luca Reggiani-Bonetti, Valeria Barresi, Antonio Manenti, Federica Domati, Alberto Farinetti
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?